PET radioligand binding to the 18-kD Translocator Protein (TSPO) in brains of patients with multiple sclerosis (MS) primarily reflects activated microglia and macrophages. We previously developed genetic stratification for accurate quantitative estimation of TSPO using second generation PET radioligands. In this study, we used 18 F-PBR111 PET and MRI to measure relative binding in lesional, peri-lesional, and surrounding normal appearing white matter of MS patients, as an index of the innate immune response.
INTRODUCTION
A prominent neuropathological feature of Multiple Sclerosis (MS) is the activation of microglia, resident brain innate immune response cells, in the white matter (WM) particularly within demyelinating lesions, but also extending into adjacent WM tissue (1) (2) (3) (4) .
MRI markers specifically associated with microglial and macrophage activation are limited.
Correlational post-mortem neuropathology and MRI in MS have confirmed that T1-weighted gadolinium (Gd) contrast enhancement and associated T2-weighted hyperintensity changes in WM reflect the adaptive immune response, but do not specifically inform on relative macrophage or microglial involvement (5) . T2-weighted white matter hyperintensities also are non-specifically associated with other pathological features including demyelination, axonal loss and astrogliosis (6) . A recent study found that subtle reductions in the MRI magnetization transfer ratio (MTR) in peri-lesional WM volumes are associated with increased microglia density (7) . However, decreases in MTR reflect other changes in tissue microstructure, such as demyelination, as well and do not provide specific biomarker for innate immune activation.
PET radioligand binding to the 18-kD Translocator Protein (TSPO) in brains of patients with MS primarily reflects activated microglia and macrophages (8, 9) . However, the interpretation of the findings of early studies, using the first generation PET tracer 11 C-(R)-PK11195, is limited by the rather poor signal-to-noise ratio for this tracer and non-specific binding, which challenge accurate quantitation of the signal (8, (10) (11) (12) .
A number of second generation TSPO PET radioligands with improved signal-to-noise ratio relative to 11 C-(R)-PK11195, have been developed (13) . Unexpectedly, the first two studies using newer TSPO radioligands did not report increases in WM binding of MS patients relative to healthy controls (14, 15) . However, the analyses did not take into consideration the Colasanti et al. 18 F-PBR111 PET in Multiple Sclerosis 6 population variation in binding of radioligands associated with the rs6971 TSPO gene single nucleotide polymorphism (SNP) (16) 
MATERIALS AND METHODS

Study Design
This was an open-label study in patients with relapsing-remitting MS and age-matched healthy volunteers (n=11 per group, see Supplemental Data for details). All subjects were genotyped for the rs6971 SNP, that determines variations in affinity between subjects (who express either a
Colasanti et al. 18 F-PBR111 PET in Multiple Sclerosis 7 high affinity (HAB) or low affinity (LAB) or co-expression of both binding states (MAB)) for second-generation TSPO radioligands (16) . Patients with MS and healthy volunteers were matched for the rs6971 SNP (Supplemental Table 1 ).
Each participant underwent an MRI scan and a 18 F-PBR111 PET scan on the same day. Four healthy volunteers and one MS patient (all HABs) underwent a second 18 F-PBR111 PET scan on the following day in order to evaluate the reproducibility of the PET signal.
Disability was assessed by an experienced consultant neurologist using the Expanded Disability Status Scale (EDSS). The Multiple Sclerosis Severity Score (MSSS) was calculated based on EDSS scores and disease duration according to Roxburgh et al. (21) .
Imaging Methods
Details on radioligand synthesis, PET protocol and MRI protocol are described in the Supplemental Data. The remaining WM in the MS patients (remaining after exclusion of the T2-FLAIR hyperintense lesions) was further segmented to three Volumes of Interest (VOIs) as follows:
perilesional volumes, including voxels within a 6 mm-thick volume disposed around T2-Colasanti et al. 18 F-PBR111 PET in Multiple Sclerosis 8 hyperintense lesions (Fig. 1A and B) ; non-lesional low MTR (NLLM) voxels, with MTR ranging between 90-98% of the non-lesional mean WM MTR (7) (Fig. 1C) A two-tissue compartment kinetic model with a metabolite-corrected plasma input function was applied to the dynamic PET data using a fixed blood volume correction of 5% (19) . For each VOI examined, the total Volume of Distribution (VT) was estimated from the rate constants as described previously (22) . The Logan graphical method (23) employing a plasma input, using a fixed blood volume correction of 5% and a linear start time at 35 minutes was also used to estimate the VT of each VOI and further applied at the voxel level to produce parametric VT maps. Model fitting and parameter estimation was performed using software implemented in Matlab R2008b (The MathWorks Inc., Natick, MA, USA).
Summary of statistics
We expressed 18 F-PBR111 VT for the whole WM as V T WM . For each subject the mean 18 F-PBR111 VT uptake of all lesions larger than 100 voxels (V T L ) and perilesional volumes (V T PL ), respectively, was computed. Uptake of 18 F-PBR111 in NLLM and NLHM were expressed as V T NLLM and V T NLHM , respectively. We used non-parametric statistic analysis with contrasts of
Similarly we used non-parametric tests for the contrasts within MS patients ( V T L , V T PL , and V T NLLM were separately compared to V T NLHM ). Details of the statistical analyses are presented in the Supplemental Methods. The relative increase (Δ) in 18 F-PBR111 uptake in lesions, perilesional, and NLLM volumes vs NLHM, was computed as follows:
The variability across individual lesions, within each MS patient, was expressed using the coefficient of variation (CV) in V T L across individual lesions, as follows:
Test-retest variability of V T WM was studied in four healthy volunteers and one MS patient, and was expressed as the absolute difference between the two consecutive days scans divided by the mean of the two scans. For the MS patient who was studied twice in consecutive days, we assessed test-retest variability of individual V T L and V T PL . Additionally, we calculated test-retest variability of individual normalized lesional and perilesional Distribution Volume Ratio (DVR)
by normalising the corresponding VT values by V T NLHM . The DVR was computed as follows:
Details on correlational analyses are presented in the Supplemental Methods.
RESULTS
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The demographic and clinical characteristics of study participants are presented in Supplemental 
Between Subjects Contrasts
We observed a significant effect of TSPO genotype on WM binding of 18 
Whole white matter
We saw a trend towards lower whole WM binding in healthy controls compared to MS patients Fig. 3 and Supplemental Fig.   1 ).
Within Subjects Contrasts
Relative 18 F-PBR111 VT values for individual lesions and perilesional volumes, and in the NLHM and NLLM voxels, are presented separately for each MS patient (see Fig. 4 ). The median CV in V T L across individual lesions within the patients was 15.2% (range, 9 -25%).
We found VT in lesional (ΔL, 10.7% (-9. Table 1 , case 4), focal areas of increased radiotracer binding correspond poorly with T2 hyperintense regions of WM (Fig. 5, D-F ).
Disease severity, as assessed from MSSS scores, correlated with the mean 18 F-PBR111 VT increase in lesions for each patient (expressed relative to that in individual NLHM WM) (Spearman's =0.62; p=0.05; Fig. 6 ).
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Test-Retest Reproducibility
The test-retest variability in 18 Post-mortem autoradiographic studies in brains of patients with MS have consistently demonstrated that increased uptake of TSPO-targeted radioligands co-localizes with markers of activated microglia (8, 11, 25, 26) . An immunohistochemical analysis of post-mortem MS brain
F-PBR111 PET in Multiple Sclerosis 13
tissue was largely consistent with these findings, suggesting that most cells expressing TSPO in acute MS lesions were macrophages or microglia (9), although it should be cautioned that antibody-based localization of the TSPO peptide and expression of the binding domain for the TSPO radioligands need not be the same. In a relapsing-remitting EAE model (18), increased 18 F-PBR111 uptake co-localizes with activated microglia and macrophages and parallels the temporal dynamics of their up regulation during experimentally induced relapses.
We observed an increased 18 The hypercellular margin, characterized by a high density of activated microglia surrounding demyelinating plaques, is a consistent finding across neuropathological studies (2, 28, 29) .
By contrast, approximately one third of the MRI-defined lesions and perilesional volumes were associated with 18 F-PBR111 uptake similar to, or lower than, that of the normal appearing NLHM WM. Case 4 (Fig. 5, bottom row) is an illustrative example of poor correspondence between areas of increased 18 F-PBR111 VT and T2 FLAIR hyperintensities. We speculate that these volumes represent chronic inactive lesions that are hypocellular or have enlarged extracellular spaces leading to a relatively low density of all cells, including microglia. Our findings of regional variation thus are consistent with post-mortem pathology observations in MS patients.
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The median within-subject CV in lesional 18 F-PBR111 uptake was above 15%. This indicates a moderately high variability of the observed Alternatively, WM microglial activation in the absence of inflammatory demyelination may represent secondary reactive changes, perhaps associated with Wallerian degeneration (32) .
Direct tests of these alternative hypotheses now seem possible using serial MRI observations to follow the course of these WM changes identified by TSPO PET.
Although this work has gone further than previous studies in using a second generation TSPO radioligand for MRI image-correlated quantitative analyses, our findings are in general agreement with those of some TSPO-targeted PET studies in MS. Previous work using 11 C-(R)-PK11195 demonstrated increased uptake to correspond to WM Gd-enhancing lesions (8, 10, 11) . One early study suggested the presence of focal areas of increased uptake in normal appearing white (and grey) matter (8) . However, patterns of ligand uptake in T2-weighted hyperintensities, and correlations between 11 C-(R)-PK11195 uptake and disease duration and
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disability have been inconsistent in previous studies (8, 10, 33) . This could reflect differences in patient populations, differences in the proportion of specific (displaceable) signal between 18 F-PBR111 and 11 C-(R)-PK11195 or accurate modeling, which is particularly challenging for the lower affinity 11 C-(R)-PK11195 (24, 34) .
This is the first study using a second generation TSPO ligand to successfully detect significant differences in radioligand uptake between MS patients and healthy controls. The lack of differences seen in previous studies may be explained by failure to control for the variance introduced by the rs6971 TSPO SNP (14, 15) .
There are a number of limitations of our study.
We studied only a small number of patients. Further characterization of the heterogeneity of the disease is needed. The use of disease-modifying treatments in the majority of MS patients studied may have influenced the 18 F-PBR111 signal. A study by Ratchford and colleagues showed a 3.2% reduction in 11 C-(R)-PK11195 in relapsing-remitting MS patients after 1-year treatment with glatiramer acetate, for example (35) . This estimate of treatment effect is much lower than the differences in binding we found between healthy volunteers and patients overall,
however (approximately 40% in the whole white matter). However, in future work, it will be important to investigate the effects of various MS treatments on TSPO specific binding.
MS patients and healthy controls were not matched for gender, although to our knowledge there have been no reports of a gender effect on TSPO binding in humans. Studies in rodents suggested a higher number of microglia and astrocytes in adult females (36, 37) , so we cannot exclude the possibility that a higher prevalence of women in the MS group may have contributed to the higher 18 F-PBR111 VT in patients.
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Finally, increased TSPO is seen not just in activated microglia, but also in rare, activated astrocytes (9) and in lymphocytes (38) , as well as in brain vascular endothelia (39) . The interpretation of increased 18 F-PBR111 VT reported here as arising largely from activated macrophages or microglia is based on prior neuropathological studies demonstrating large numbers of these cells post-mortem in the regions studied and on the relatively high binding to them relative to other inflammatory cells (2, (27) (28) (29) . A contribution from other inflammatory cell types cannot be excluded, but binding (Bmax) to lymphocytes is relatively much lower (40) .
Further technical aspects are considered in the Supplemental Data.
CONCLUSION
This study demonstrates that quantitative TSPO PET with a second generation radioligand is sensitive to an element of the inflammatory response in MS not apparent on MRI and so otherwise occult in vivo. It highlights opportunities for the integration of MRI and molecular imaging for understanding the evolution of the dynamic neuropathology of MS. The upper row illustrates a patient with recent active disease (Supplemental Table 1 , case 9).
Here, T2 FLAIR hyperintense lesional areas correspond to areas of increased 18 F-PBR111
signal. The lower row illustrates a patient (Supplemental Table 1 , case 4) with a relatively benign disease course showing focal regions of increased 18 F-PBR111 VT that correspond poorly to T2 FLAIR hyperintense areas. 
